2. Academic Validation
  3. Identifying CTSF and GSTM3 as chemoresistance therapeutic targets in breast cancer through multi-omics MR analysis

Identifying CTSF and GSTM3 as chemoresistance therapeutic targets in breast cancer through multi-omics MR analysis

  • iScience. 2025 Oct 30;28(12):113908. doi: 10.1016/j.isci.2025.113908.
Rui Liu 1,  Ying Yao 2,  Zhihua Lv 1,  Jingtao Huang 1
Affiliations

Affiliations

  • 1 Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
  • 2 Department of Pharmacy, Wuxi Maternity and Child Health Care Hospital, Women's Hospital of Jiangnan University, Wuxi 214002, China.
PMID: 41321627 DOI: 10.1016/j.isci.2025.113908
Abstract

Breast Cancer is a leading cause of cancer-related mortality worldwide, with drug resistance remaining a major therapeutic challenge. We integrated multi-omics data-including GWAS, eQTL, and pQTL-with Mendelian randomization to identify genes associated with breast Cancer risk and therapy response. Our analyses revealed CTSF and GSTM3 as key candidates, showing consistent associations at both RNA and protein levels. Functional studies indicated that CTSF expression correlates with taxane resistance but cyclophosphamide sensitivity, while GSTM3 influences response across multiple regimens. Enrichment analyses suggest roles in immune and hormone signaling pathways. These findings highlight CTSF and GSTM3 as potential biomarkers and therapeutic targets for overcoming chemoresistance in breast Cancer.

Keywords

bioinformatics; health sciences; medical informatics; medical specialty; medicine; oncology.

Figures
Products